Double antibody attack: new hope for tough pancreatic cancer?
NCT ID NCT07176702
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding a new antibody called HLX22 to standard treatment (trastuzumab plus chemotherapy) can shrink tumors and improve survival in people with HER2-positive pancreatic cancer that has spread. The study enrolls 45 adults who have not had prior treatment for metastatic disease. Participants receive the drug combination every three weeks until the cancer worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HLX22 (a lab-made antibody targeting HER2) combined with trastuzumab (another HER2 antibody) and chemotherapy (nab-paclitaxel and gemcitabine)
- What this could lead to
- If it works, this could point toward a more effective first-line treatment for HER2-positive pancreatic cancer, potentially shrinking tumors and extending survival.
- What could go wrong
- This is a small, early-phase trial (45 people) with no results yet. The added antibodies may cause more side effects or not improve outcomes over standard chemo alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE STATUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Nanjing, 210008, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200233, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.